The landscape of cancer treatment is currently undergoing a paradigm shift, moving away from broad-spectrum chemotherapies toward highly personalized, cellular-based interventions. At the forefront of this revolution is Adoptive Cell Therapy (ACT), a category of immunotherapy that empowers a patient’s own immune system to recognize and eliminate malignant cells. To synthesize the latest breakthroughs and address the persistent hurdles in this field, the prestigious journal OncoImmunology, published by Taylor & Francis, has officially issued a call for submissions for a new, comprehensive Article Collection: "Advances in Adoptive Cell Therapies."
This initiative aims to curate a definitive repository of pre-clinical, translational, and clinical research, inviting the global scientific community to contribute to the next generation of cancer care.
Main Facts: The Frontier of ACT
Adoptive cell therapy involves the isolation and expansion of immune cells—typically T cells—from a patient, which are then modified or activated in a laboratory setting before being re-infused into the patient. The primary goal is to bolster the immune system’s ability to hunt down and eradicate cancer cells that have historically evaded detection.
The Rise of CAR-T and Beyond
The success of Chimeric Antigen Receptor (CAR-T) cell therapies in treating hematologic malignancies, such as B-cell leukemias and lymphomas, has provided the "proof of concept" necessary to expand the scope of ACT. However, the current call for papers seeks to look beyond these initial successes. The scope of the collection includes, but is not limited to:
- Next-Generation CAR-T: Moving beyond traditional targets to address solid tumors.
- TIL Therapies: Advancements in Tumor-Infiltrating Lymphocytes.
- TCR-T Therapies: Engineering T-cell receptors to target intracellular antigens.
- Off-the-Shelf Solutions: Moving toward allogeneic, "ready-to-use" cell products to reduce manufacturing lead times.
The collection serves as a platform for researchers to address the "bottlenecks" of current therapies—namely, the high cost, the arduous manufacturing timelines, and the often-debilitating toxicities associated with rapid immune activation.
Chronology: A Brief History of Adoptive Cell Therapy
The trajectory of ACT has been defined by decades of incremental scientific discovery punctuated by moments of clinical triumph.
- 1980s–1990s: The Foundations of TILs. Dr. Steven Rosenberg and his team at the National Cancer Institute (NCI) pioneered the use of tumor-infiltrating lymphocytes (TILs), demonstrating that immune cells harvested directly from a patient’s tumor could induce regression in metastatic melanoma.
- 2000s: The Emergence of Chimeric Antigen Receptors. Researchers began engineering synthetic receptors—CARs—that combine the specificity of antibodies with the killing machinery of T cells. Early iterations laid the groundwork for the clinical successes that would follow.
- 2012: The Emily Whitehead Milestone. The high-profile success of CAR-T therapy in pediatric B-cell acute lymphoblastic leukemia (ALL) brought global attention to the potential of cellular immunotherapy.
- 2017: FDA Approval. The U.S. Food and Drug Administration (FDA) approved the first CAR-T cell therapies (Kymriah and Yescarta), marking the official entry of ACT into mainstream oncology.
- 2024–2026: The Expansion Phase. As we look toward 2026, the field is shifting from "demonstrating feasibility" to "optimizing delivery." The current OncoImmunology call for papers is set within this context, aiming to bridge the gap between initial clinical success and widespread, safe, and cost-effective application.
Supporting Data: Challenges in the Current Paradigm
Despite the enthusiasm surrounding ACT, the clinical reality is nuanced. Current data highlights several critical areas that the OncoImmunology collection hopes to illuminate:
1. The Manufacturing Bottleneck
Currently, the "vein-to-vein" time for CAR-T therapy can take weeks, during which a patient’s cancer may progress. The complexity of Good Manufacturing Practice (GMP) facilities and the reliance on bespoke, patient-specific production remain the primary drivers of the exorbitant costs associated with these therapies.
2. The Solid Tumor Barrier
While CAR-T has been highly effective in liquid tumors (blood cancers), solid tumors present a hostile microenvironment. These tumors are characterized by:
- Physical barriers: Dense extracellular matrices that prevent T-cell infiltration.
- Metabolic competition: Tumors consume nutrients, leaving T cells starved.
- Immunosuppression: The tumor microenvironment actively inhibits T-cell function via checkpoint pathways (e.g., PD-1, CTLA-4).
3. Toxicity and Antigen Escape
Severe toxicities, such as Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS), remain significant risks. Furthermore, tumors are evolutionarily dynamic; they often "escape" treatment by downregulating or losing the specific antigen the CAR-T cells were designed to recognize. Research into multi-targeted CARs and combination therapies is essential to mitigate these risks.
Official Perspectives: The Editorial Vision
The decision by Taylor & Francis to dedicate a specific Article Collection to this topic signals an acknowledgement of the urgency in this field. By hosting this collection within OncoImmunology, the publisher ensures that the research will reach a specialized audience of immunologists, clinical oncologists, and biotechnology developers.
Why Peer Review Matters
The submission guidelines emphasize that all manuscripts will undergo a rigorous, full peer-review process. OncoImmunology maintains a high standard for scientific integrity, ensuring that as the field moves toward more aggressive and experimental therapies, the underlying data remains robust and reproducible.
The Role of the Guest Advisor
To maintain transparency and impartiality, the Guest Advisor for this collection will not be involved in the editorial handling of individual manuscripts, unless they are a sitting member of the Editorial Board. This firewall ensures that the submission process remains objective and focused purely on the scientific merit of the contributions.
Implications: The Path Forward for Cancer Care
The invitation to submit work to this collection is more than a call for papers; it is a call for a transformation in medical practice. The implications for the future of oncology are profound.
Personalized Medicine at Scale
The ultimate goal of the research sought by this collection is to move ACT from a "last-resort" treatment to a foundational pillar of cancer care. If researchers can overcome the hurdles of persistence and infiltration, ACT could theoretically be used earlier in the treatment continuum, significantly improving long-term survival rates.
The Integration of AI and Biotechnology
The collection is also expected to feature papers integrating computational biology. As we generate more data on how T cells interact with tumor environments, machine learning models will play an increasing role in predicting patient response and designing more effective synthetic receptors.
Addressing Health Equity
By addressing the labor-intensive nature of manufacturing, the research solicited in this call has the potential to eventually lower the cost of goods. This is a vital step toward ensuring that cutting-edge therapies are accessible not just in high-resource clinical settings, but globally.
How to Contribute
Researchers and clinicians working in the field of adoptive cell therapy are encouraged to review the OncoImmunology journal scope and author submission instructions carefully.
- Submission Deadline: December 31, 2026.
- Process: Authors must ensure they select the "Advances in Adoptive Cell Therapies" Article Collection from the drop-down menu in the submission portal.
- Inquiries: For questions regarding eligibility, scope, or potential discount codes for publication, interested parties are invited to contact Rebecca Turner.
A Final Note on the Future
As the global community converges on the goal of curing cancer, initiatives like this one serve as the connective tissue that binds disparate laboratory discoveries into a coherent clinical strategy. The coming years, leading up to the 2026 deadline, are expected to be among the most transformative in the history of immunotherapy. By contributing to this collection, researchers are not merely submitting a paper; they are actively participating in the blueprint for the next century of oncological medicine.
For those interested in participating, additional information can be found at the official Taylor & Francis Article Collection page. The opportunity to shape the future of medicine is open, and the global oncology community stands ready to see what breakthroughs will emerge from this call.
About the Author
